한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제27권2호
  • /
  • Pages.99-104
  • /
  • 2017
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지
DOI QR코드

DOI QR Code

제 2형 당뇨병 환자에서 Metformin과 병용 시 Dapagliflozin과 Sitagliptin의 효능 비교

Comparisons of Efficacy between Dapagliflozin and Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus Patients

  • 강보경 (이화여자대학교 임상보건융합대학원) ;
  • 안숙희 (원광대학교 약학대학) ;
  • 김재연 (서울아산병원 약제팀) ;
  • 곽혜선 (이화여자대학교 임상보건융합대학원)
  • Kang, Bo Kyeong (Graduate School of Clinical & Public Health Convergence, Ewha Womans University) ;
  • An, Sook Hee (College of Pharmacy, Wonkang University) ;
  • Kim, Jae Youn (Division of Pharmaceutical Services, Asan Medical Center) ;
  • Gwak, Hye Sun (Graduate School of Clinical & Public Health Convergence, Ewha Womans University)
  • 투고 : 2017.06.26
  • 심사 : 2017.06.27
  • 발행 : 2017.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: This study aimed to compare effects on glycemic control and weight loss between the metformin/dapagliflozin combination and the metformin/sitagliptin combination in type 2 diabetic patients. Methods: This study retrospectively reviewed the medical records, from January $1^{st}$ 2015 to March $31^{st}$ 2016, of type 2 diabetic patients who were older than 18 and were prescribed with dapagliflozin or sitagliptin in combination with metformin. Hemoglobin $A_{1c}$ ($HbA_{1c}$) levels and weights were measured every 3 months. Results: The dapagliflozin group showed a greater decrease in $HbA_{1c}$ levels after 3 months (-0.75% vs. 0.01%, P<0.001), 6 months (-0.36% vs. 0.08%, P=0.029), and 9 months (-0.53% vs. 0.08%, P=0.046) compared to the sitagliptin group. Also, the dapagliflozin group showed a greater significant decrease in the rate of change in $HbA_{1c}$ levels after 3 months (-0.09 vs. 0.01, P<0.001), 6 months (-0.04 vs. 0.01, P=0.031), 9 months (-0.07 vs. 0.02, P=0.029), and 12 months (-0.05 vs. 0.05, P=0.047). Furthermore, the dapagliflozin group showed a greater decrease in amount of weight change after 3 months (-2.46 kg vs. 0.37 kg, P<0.001), 6 months (-3.02 kg vs. 0.13 kg, P<0.001), and 9 months (-2.27 kg vs. 0.50 kg, P=0.002). Finally, the dapagliflozin group showed a greater decrease in the rate of change in weight after 3 months (-3.10% vs. 0.52%, P<0.001), 6 months (-3.83% vs. 0.21%, P<0.001), 9 months (-2.84% vs. 0.79%, P=0.002), and 12 months (-4.91% vs. 0.44%, P<0.001). Conclusions: It was concluded that dapagliflozin is more effective than sitagliptin for type 2 diabetic patients.

키워드

참고문헌

  1. Available form http://kostat.go.kr/portal/korea/index.action. Accessed April 12, 2017.
  2. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle Interventions for Patients With and at Risk for Type 2 DiabetesA Systematic Review and Meta-analysis. Ann Intern Med 2013;159(8):543-51. https://doi.org/10.7326/0003-4819-159-8-201310150-00007
  3. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-50. https://doi.org/10.1056/NEJM200105033441801
  4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89. https://doi.org/10.1056/NEJMoa0806470
  5. Oh JY. Treatment guideline for diabetes. Korean J Intern Med 2008;75(3):249-56.
  6. FDA(R), Available form http://www.accessdata.fda.gov/scripts/cder/ drugsatfda. Accessed April 12, 2017.
  7. Kimsonline(R), Available form http://www.kimsonline.co.kr. Accessed April 12, 2017.
  8. Uptodate(R), Available form http://www.uptodate.com. Accessed April 12, 2017.
  9. Bailey CJ, Gross JL, Pieters A, Bastien A. List J.F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223-33. https://doi.org/10.1016/S0140-6736(10)60407-2
  10. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin addon to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013;11:193. https://doi.org/10.1186/1741-7015-11-193
  11. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97(3):1020-31. https://doi.org/10.1210/jc.2011-2260
  12. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13(10):928-38. https://doi.org/10.1111/j.1463-1326.2011.01434.x
  13. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35(7):1473-8. https://doi.org/10.2337/dc11-1693
  14. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24 week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37(3):740-50. https://doi.org/10.2337/dc13-0467
  15. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin in monotherapy in type 2 diabetes patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase 3 trial. Diabetes Care 2010;33(10):2217-24. https://doi.org/10.2337/dc10-0612
  16. Zhang Y, Hong J, Chi J, et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014;30(3):241-56. https://doi.org/10.1002/dmrr.2482
  17. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369-83. https://doi.org/10.1136/bmj.e1369
  18. DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a metaanalysis of randomized clinical trials. Diabet Med 2010;27(3):309-17. https://doi.org/10.1111/j.1464-5491.2010.02941.x
  19. Bloomgarden ZT, Dodis R, Viscoli CM, et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy. Diabetes Care 2006;29(9):2137-9. https://doi.org/10.2337/dc06-1120
  20. Skolnik N, Bonnes H, Yeh H, Katz A. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C. Postgrad Med 2016;128(4):356-63. https://doi.org/10.1080/00325481.2016.1173514
  21. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjostrom CD. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab. 2014;16(7):645-50. https://doi.org/10.1111/dom.12263

피인용 문헌

  1. 한약 복용이 제 2형 당뇨 환자의 혈당 변화에 미치는 영향 : 후항적 차트 리뷰 vol.41, pp.6, 2017, https://doi.org/10.22246/jikm.2020.41.6.1066